Auton TR - Search Results

1

From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug.

Lock EA, Ellis MK, Gaskin P, Robinson M, Auton TR, Provan WM, Smith LL, Prisbylla MP, Mutter LC, Lee DL. Lock EA, et al. Among authors: auton tr. J Inherit Metab Dis. 1998 Aug;21(5):498-506. doi: 10.1023/a:1005458703363. J Inherit Metab Dis. 1998. PMID: 9728330 Review.

2

Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione.

Ellis MK, Whitfield AC, Gowans LA, Auton TR, Provan WM, Lock EA, Smith LL. Ellis MK, et al. Among authors: auton tr. Toxicol Appl Pharmacol. 1995 Jul;133(1):12-9. doi: 10.1006/taap.1995.1121. Toxicol Appl Pharmacol. 1995. PMID: 7597701

3

Characterization of the interaction of 2-[2-nitro-4-(trifluoromethyl)benzoyl]-4,4,6,6,-tetramethyl- cyclohexane-1,3,5-trione with rat hepatic 4-hydroxyphenylpyruvate dioxygenase.

Ellis MK, Whitfield AC, Gowans LA, Auton TR, Provan WM, Lock EA, Lee DL, Smith LL. Ellis MK, et al. Among authors: auton tr. Chem Res Toxicol. 1996 Jan-Feb;9(1):24-27. doi: 10.1021/tx950100w. Chem Res Toxicol. 1996. PMID: 8924597

4

Application of benchmark dose risk assessment methodology to developmental toxicity: an industrial view.

Foster PM, Auton TR. Foster PM, et al. Among authors: auton tr. Toxicol Lett. 1995 Dec;82-83:555-9. doi: 10.1016/0378-4274(95)03584-2. Toxicol Lett. 1995. PMID: 8597110

5

Calculation of benchmark doses from teratology data.

Auton TR. Auton TR. Regul Toxicol Pharmacol. 1994 Apr;19(2):152-67. doi: 10.1006/rtph.1994.1014. Regul Toxicol Pharmacol. 1994. PMID: 8041913

6

Thresholds in chemical carcinogenesis.

Purchase IF, Auton TR. Purchase IF, et al. Among authors: auton tr. Regul Toxicol Pharmacol. 1995 Dec;22(3):199-205. doi: 10.1006/rtph.1995.0001. Regul Toxicol Pharmacol. 1995. PMID: 8837843

7

Pharmacokinetics of fluazifop-butyl in human volunteers. II: Dermal dosing.

Ramsey JD, Woollen BH, Auton TR, Batten PL, Leeser JE. Ramsey JD, et al. Among authors: auton tr. Hum Exp Toxicol. 1992 Jul;11(4):247-54. doi: 10.1177/096032719201100402. Hum Exp Toxicol. 1992. PMID: 1354971

8

A physiologically based mathematical model of dermal absorption in man.

Auton TR, Westhead DR, Woollen BH, Scott RC, Wilks MF. Auton TR, et al. Hum Exp Toxicol. 1994 Jan;13(1):51-60. doi: 10.1177/096032719401300108. Hum Exp Toxicol. 1994. PMID: 8198830

9

Modelling dermal pharmacokinetics using in vitro data. Part II. Fluazifop-butyl in man.

Auton TR, Ramsey JD, Woollen BH. Auton TR, et al. Hum Exp Toxicol. 1993 May;12(3):207-13. doi: 10.1177/096032719301200303. Hum Exp Toxicol. 1993. PMID: 8100431

10

Vehicle effects on in vitro percutaneous absorption through rat and human skin.

Hilton J, Woollen BH, Scott RC, Auton TR, Trebilcock KL, Wilks MF. Hilton J, et al. Among authors: auton tr. Pharm Res. 1994 Oct;11(10):1396-400. doi: 10.1023/a:1018931503784. Pharm Res. 1994. PMID: 7855041

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page